Protective effects of simvastatin and/or telmisartan on cardiovascular system in patients with mild to moderate chronic obstructive pulmonary disease (COPD).

Abstract

Abstract:The objective of this study is to evaluate the protective effects ofsimvastatin, telmisartan or their combination on cardiovascular system inpatients with COPD.Eighty patients with mild to moderate COPD were participated in thisstudy. They were recruited into four groups where the first group includes 20patients on an inhaled β2- agonist only (control), the second group includes 20patients on an inhaled β2- agonist plus 20mg/d simvastatin, the third groupincludes 20 patients on an inhaled β2- agonist plus 40mg/d telmisartan and thefourth group includes 20 patients on an inhaled β2- agonist plus combination ofboth simvastatin and telmisartan. Twenty apparently healthy subjects wereselected to be a normal group for comparison. Baseline, 3 and 6 months periodswere used to monitor patients. Assessing the plasma levels of hs-CRP, VCAM-1and lipid profile. ANOVA method for statistics were used to compare theresults.There was a great reduction in hs-CRP and VCAM-1 in addition tomodulation of lipid profile after the use of simvastatin 20mg/d, telmisartan40mg/d and their combination in COPD patients.Simvastatin 20mg/d, telmisartan 40mg/d and their combination exerted aprotective effect on the cardiovascular system in COPD patients after 3 and 6months of therapy by reducing hs-CRP, VCAM-1 and lipid profile.